Once-weekly diabetes drug backed in draft NICE guidance

Once-weekly type-2 diabetes drug exenatide has been recommended for third-line use in draft guidance from NICE.

NICE draft guidance recommends exenatide
NICE draft guidance recommends exenatide

Exenatide prolonged release has been recommended for use with metformin in addition to either a sulphonylurea or a thiazolidinedione. Its use should be restricted to people HbA1c levels above 7.5% and a BMI over 35 or who are unsuitable for insulin therapy, NICE has said.

The draft recommends that long-acting exenatide should only be used for patients unsuitable for triple therapy with any three of: metformin, a sulphonylurea, a thiazolidinedione and a dipeptidyl peptidase-4 inhibitor.

NICE’s draft guidance on long-acting exenatide is open for consultation until 8 November, with final guidance likely to be published in February 2012.

Commenting on the draft decision, Professor Carole Longson, director of the health technology evaluation centre at NICE said: ‘Type-2 diabetes is becoming increasingly more common in adults, so we are pleased to recommend exenatide as a treatment option for some people with the condition.’

Long-acting exenatide is marketed by Eli Lilly as Bydureon suspension for injection.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus